Dose finding studies on flucytosine in patients with fungi in their urine

Satoshi Uno; Tadasu Takenaka; Yoshio Nishitani; Toshihide Hayashi; Kazuhiro Hata; Noriaki Ono; Masaya Tsugawa; Hiromi Kumon; Hiroyuki Ohmori; Katsuichi Nanba; Yoshikatu Kondoh; Teruhisa Ohashi; Shin Irie; Tetuzou Kaneshige; Hiroyuki Kawahara; Hiroyoshi Tanaka; Shouichi Yamamoto; Motoyoshi Takada; Daisuke Yamada; Toshihiko Asai; Yasuhiro Katayama; Teruaki Akaeda; Akihiro Mizuno; Noritaka Ishito; Nobuyuki Akazawa; Mikio Kishi; Ryouji Nasu; Naoki Mitsuhata; Shunji Hayata; Yasutomo Nasu; Toshiki Yamamoto; Takafumi Akagi; Masanobu Tanimura; Seiichi Kataoka; Yukitoshi Fujita; Yoshikazu Hirai; Yasuhiro Kanemasa; Yasuichi Saitoh

doi:10.11250/chemotherapy1953.40.1263

Dose finding studies on flucytosine in patients with fungi in their urine

Satoshi Uno, Tadasu Takenaka, Yoshio Nishitani, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Yoshikatu Kondoh, Teruhisa Ohashi, Shin Irie, Tetuzou Kaneshige, Hiroyuki Kawahara, Hiroyoshi Tanaka, Shouichi Yamamoto, Motoyoshi Takada, Daisuke Yamada, Toshihiko AsaiYasuhiro Katayama, Teruaki Akaeda, Akihiro Mizuno, Noritaka Ishito, Nobuyuki Akazawa, Mikio Kishi, Ryouji Nasu, Naoki Mitsuhata, Shunji Hayata, Yasutomo Nasu, Toshiki Yamamoto, Takafumi Akagi, Masanobu Tanimura, Seiichi Kataoka, Yukitoshi Fujita, Yoshikazu Hirai, Yasuhiro Kanemasa, Yasuichi Saitoh

研究成果 › 査読

1 被引用数 (Scopus)

抄録

In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.

本文言語	English
ページ（範囲）	1263-1272
ページ数	10
ジャーナル	CHEMOTHERAPY
巻	40
号	10
DOI	https://doi.org/10.11250/chemotherapy1953.40.1263
出版ステータス	Published - 10月 1992
外部発表	はい

ASJC Scopus subject areas

薬理学（医学）
感染症
薬理学
創薬
腫瘍学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.11250/chemotherapy1953.40.1263

他のファイルとリンク

Scopusの出版物のリンク

引用スタイル

Uno, S., Takenaka, T., Nishitani, Y., Hayashi, T., Hata, K., Ono, N., Tsugawa, M., Kumon, H., Ohmori, H., Nanba, K., Kondoh, Y., Ohashi, T., Irie, S., Kaneshige, T., Kawahara, H., Tanaka, H., Yamamoto, S., Takada, M., Yamada, D., ... Saitoh, Y. (1992). Dose finding studies on flucytosine in patients with fungi in their urine. CHEMOTHERAPY, 40(10), 1263-1272. https://doi.org/10.11250/chemotherapy1953.40.1263

Uno, S, Takenaka, T, Nishitani, Y, Hayashi, T, Hata, K, Ono, N, Tsugawa, M, Kumon, H, Ohmori, H, Nanba, K, Kondoh, Y, Ohashi, T, Irie, S, Kaneshige, T, Kawahara, H, Tanaka, H, Yamamoto, S, Takada, M, Yamada, D, Asai, T, Katayama, Y, Akaeda, T, Mizuno, A, Ishito, N, Akazawa, N, Kishi, M, Nasu, R, Mitsuhata, N, Hayata, S, Nasu, Y, Yamamoto, T, Akagi, T, Tanimura, M, Kataoka, S, Fujita, Y, Hirai, Y, Kanemasa, Y & Saitoh, Y 1992, 'Dose finding studies on flucytosine in patients with fungi in their urine', CHEMOTHERAPY, vol. 40, no. 10, pp. 1263-1272. https://doi.org/10.11250/chemotherapy1953.40.1263

@article{a830e11f5dc3430db9f309bd6b3bb8b5,

title = "Dose finding studies on flucytosine in patients with fungi in their urine",

abstract = "In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.",

keywords = "flucytosine",

author = "Satoshi Uno and Tadasu Takenaka and Yoshio Nishitani and Toshihide Hayashi and Kazuhiro Hata and Noriaki Ono and Masaya Tsugawa and Hiromi Kumon and Hiroyuki Ohmori and Katsuichi Nanba and Yoshikatu Kondoh and Teruhisa Ohashi and Shin Irie and Tetuzou Kaneshige and Hiroyuki Kawahara and Hiroyoshi Tanaka and Shouichi Yamamoto and Motoyoshi Takada and Daisuke Yamada and Toshihiko Asai and Yasuhiro Katayama and Teruaki Akaeda and Akihiro Mizuno and Noritaka Ishito and Nobuyuki Akazawa and Mikio Kishi and Ryouji Nasu and Naoki Mitsuhata and Shunji Hayata and Yasutomo Nasu and Toshiki Yamamoto and Takafumi Akagi and Masanobu Tanimura and Seiichi Kataoka and Yukitoshi Fujita and Yoshikazu Hirai and Yasuhiro Kanemasa and Yasuichi Saitoh",

year = "1992",

month = oct,

doi = "10.11250/chemotherapy1953.40.1263",

language = "English",

volume = "40",

pages = "1263--1272",

journal = "Chemotherapy",

issn = "0009-3165",

number = "10",

}

TY - JOUR

T1 - Dose finding studies on flucytosine in patients with fungi in their urine

AU - Uno, Satoshi

AU - Takenaka, Tadasu

AU - Nishitani, Yoshio

AU - Hayashi, Toshihide

AU - Hata, Kazuhiro

AU - Ono, Noriaki

AU - Tsugawa, Masaya

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Nanba, Katsuichi

AU - Kondoh, Yoshikatu

AU - Ohashi, Teruhisa

AU - Irie, Shin

AU - Kaneshige, Tetuzou

AU - Kawahara, Hiroyuki

AU - Tanaka, Hiroyoshi

AU - Yamamoto, Shouichi

AU - Takada, Motoyoshi

AU - Yamada, Daisuke

AU - Asai, Toshihiko

AU - Katayama, Yasuhiro

AU - Akaeda, Teruaki

AU - Mizuno, Akihiro

AU - Ishito, Noritaka

AU - Akazawa, Nobuyuki

AU - Kishi, Mikio

AU - Nasu, Ryouji

AU - Mitsuhata, Naoki

AU - Hayata, Shunji

AU - Nasu, Yasutomo

AU - Yamamoto, Toshiki

AU - Akagi, Takafumi

AU - Tanimura, Masanobu

AU - Kataoka, Seiichi

AU - Fujita, Yukitoshi

AU - Hirai, Yoshikazu

AU - Kanemasa, Yasuhiro

AU - Saitoh, Yasuichi

PY - 1992/10

Y1 - 1992/10

N2 - In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.

AB - In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.

KW - flucytosine

UR - http://www.scopus.com/inward/record.url?scp=0026564024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026564024&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.1263

DO - 10.11250/chemotherapy1953.40.1263

M3 - Article

AN - SCOPUS:0026564024

SN - 0009-3165

VL - 40

SP - 1263

EP - 1272

JO - Chemotherapy

JF - Chemotherapy

IS - 10

ER -

Dose finding studies on flucytosine in patients with fungi in their urine

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル